Diagnostics account for the largest share of the market, driven by the growing demand for early disease detection and monitoring. The therapeutic segment is experiencing steady growth due to the increasing prevalence of chronic diseases and demand for effective treatments. Implants, particularly active implantable medical devices, hold significant potential as technological advancements enable minimally invasive procedures and improve patient outcomes. Recent developments include: In October 2024, SGS Société Générale de Surveillance SA announced the launch of the new CDISC Open Rules consultancy to assist pharmaceutical organizations in navigating compliance with the latest CDISC standards for clinical trial submissions. This service offers comprehensive support from initial consultation to ongoing evaluation, ensuring high-quality data and regulatory adherence. .

Financial overview and grant giving statistics of Clinical Data Interchange Standards Consortium Inc.

ACC/AHA =  American College of Cardiology/American Heart Association; ATS =  American Thoracic Society; CDISC =  Clinical Data Interchange Standards Consortium; NCI =  National Cancer Institute; SF-36 =  Short-form 36 questionnaire.

The Critical Path for Alzheimer's Disease (CPAD: http://c-path.org/programs/cpad/) CODR data base contains patient-level control arm data (6,500 patients; 24 clinical trials; MCI and AD), fully anonymized and remapped using CDISC SDTM v3.1.2 Standard. The database includes, but is not limited to, demographic information, APOE4 genotype, concomitant medications and cognitive scales (MMSE, ADAS-Cog, CDR-SB). Currently no AD fluid biomarker or imaging data are included.